文献速递糖尿病

1型糖尿病患者从每日多次注射和血糖自我监测直接转为MiniMed 780G高级混合闭环系统的转换:一项两中心随机对照研究

Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.
PubMed 文献 · Diabetes Care · 2022-01-01

这项两中心随机对照试验纳入41例使用每日多次注射和血糖自我监测、未使用过持续皮下胰岛素输注和持续葡萄糖监测的1型糖尿病成人,随机分为高级混合闭环系统组(n=20)和每日多次注射+血糖自我监测组(n=21)。3个月时,高级混合闭环系统组目标范围内时间从基线69.3±12.3%增至85.0±6.3%,对照组无变化(治疗效应21.5% [95% CI 15.7, 27.3];P < 0.001);低血糖时间(<70 mg/dL)从8.7±7.3%降至2.1±1.7%,对照组无变化(治疗效应-4.4% [95% CI -7.4, -2.1];P < 0.001);HbA1c和生活质量特定子量表也有显著改善。结论认为,未使用过持续皮下胰岛素输注和持续葡萄糖监测技术的1型糖尿病患者起始高级混合闭环系统可显著且安全地改善血糖控制及生活质量和心理幸福感。

要点

  • 高级混合闭环系统组目标范围内时间从69.3±12.3%增至85.0±6.3%,对照组无变化。
  • 高级混合闭环系统组低血糖时间(<70 mg/dL)从8.7±7.3%降至2.1±1.7%,对照组无变化。
  • 高级混合闭环系统组HbA1c和生活质量特定子量表较对照组显著改善。

核心结论

  • 未使用过持续皮下胰岛素输注和持续葡萄糖监测技术的1型糖尿病患者起始高级混合闭环系统可显著且安全地改善血糖控制、生活质量和心理幸福感。

研究设计与样本

  • 两中心、随机、对照、平行组试验,纳入26-60岁、使用每日多次注射和血糖自我监测、HbA1c <10%的1型糖尿病成人。
  • 共招募41例参与者,随机分为高级混合闭环系统组(n=20)和每日多次注射+血糖自我监测组(n=21),37例完成研究(平均±标准差年龄40.3±8.0岁,糖尿病病程17.3±12.1年,BMI 25.1±3.1 kg/m2,HbA1c 7.2±1.0%)。

主要发现

  • 高级混合闭环系统组目标范围内时间从基线69.3±12.3%增至3个月时85.0±6.3%,对照组无变化(治疗效应21.5% [95% CI 15.7, 27.3];P < 0.001)。
  • 高级混合闭环系统组低于范围时间(<70 mg/dL)从8.7±7.3%降至2.1±1.7%,每日多次注射+血糖自我监测组无变化(治疗效应-4.4% [95% CI -7.4, -2.1];P < 0.001)。
  • 与每日多次注射+血糖自我监测组相比,高级混合闭环系统组HbA1c显著改善(治疗效应-0.6% [95% CI -0.9, -0.2];P = 0.005),生活质量特定子量表也有显著改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the outcomes of transitioning to the MiniMed 780G advanced hybrid closed-loop (AHCL) system in adult individuals with type 1 diabetes mellitus (T1DM) naive to continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) technologies. RESEARCH DESIGN AND METHODS: This was a two-center, randomized, controlled, parallel-group trial with evaluation of individuals with T1DM aged 26-60 years managed with multiple daily injections (MDI) and self-monitoring of blood glucose (BGM) with HbA1c <10%. RESULTS: A total of 41 participants were recruited and randomized to either the AHCL (n = 20) or the MDI+BGM (n = 21) group, and 37 participants (mean ± SD age 40.3 ± 8.0 years, duration of diabetes 17.3 ± 12.1 years, BMI 25.1 ± 3.1 kg/m2, HbA1c 7.2 ± 1.0%) completed the study. Time spent with glucose levels in target range increased from 69.3 ± 12.3% at baseline to 85.0 ± 6.3% at 3 months in the AHCL group, while remaining unchanged in the control group (treatment effect 21.5% [95% CI 15.7, 27.3]; P < 0.001). The time with levels below range (<70 mg/dL) decreased from 8.7 ± 7.3% to 2.1 ± 1.7% in the AHCL group and remained unchanged in the MDI+BGM group (treatment effect -4.4% [95% CI -7.4, -2.1]; P < 0.001). Participants from the AHCL group also had significant improvements in HbA1c levels (treatment effect -0.6% [95% CI -0.9, -0.2]; P = 0.005) and in quality of life (QoL) in specific subscales compared with the MDI+BGM group. CONCLUSIONS: People with T1DM naive to CSII and CGM technologies initiating AHCL significantly and safely improved their glycemic control, as well as their QoL and psychological well-being.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Matejko B, Juza A, Kieć-Wilk B, et al. Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study. Diabetes Care. 2022. PMID: 35972259. doi:10.2337/dc22-0470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。